Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 7, 22

First-line Antihypertensive Treatment in Patients With Pre-Diabetes: Rationale, Design and Baseline Results of the ADaPT Investigation

Clinical Trial

First-line Antihypertensive Treatment in Patients With Pre-Diabetes: Rationale, Design and Baseline Results of the ADaPT Investigation

Walter Zidek et al. Cardiovasc Diabetol.


Background: Recent clinical trials reported conflicting results on the reduction of new-onset diabetes using RAS blocking agents. Therefore the role of these agents in preventing diabetes is still not well defined. Ramipril is an ACE inhibitor (ACEi), that has been shown to reduce cardiovascular events in high risk patients and post-hoc analyses of the HOPE trial have provided evidence for its beneficial action in the prevention of diabetes.

Methods: The ADaPT investigation ("ACE inhibitor-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes") is a 4-year open, prospective, parallel group phase IV study. It compares an antihypertensive treatment regimen based on ramipril versus a treatment based on diuretics or betablockers. The primary evaluation criterion is the first manifestation of type 2 diabetes. The study is conducted in primary care to allow the broadest possible application of its results. The present article provides an outline of the rationale, the design and baseline characteristics of AdaPT and compares these to previous studies including ASCOT-BLPA, VALUE and DREAM.

Results: Until March 2006 a total of 2,015 patients in 150 general practices (general physicians and internists) throughout Germany were enrolled. The average age of patients enrolled was 67.1 +/- 10.3 years, with 47% being male and a BMI of 29.9 +/- 5.0 kg/m2. Dyslipidemia was present in 56.5%. 37.8% reported a family history of diabetes, 57.8% were previously diagnosed with hypertension (usually long standing). The HbA1c value at baseline was 5.6 %. Compared to the DREAM study patients were older, had more frequently hypertension and patients with cardiovascular disease were not excluded.

Conclusion: Comparing the ADaPT design and baseline data to previous randomized controlled trial it can be acknowledged that AdaPT included patients with a high risk for diabetes development. Results are expected to be available in 2010. Data will be highly valuable for clinical practice due to the observational study design.


Figure 1
Figure 1
Diabetes incidence – results of full Bayesian network meta-analysis of 22 trials with 143153 patients [14], modified from [15].

Similar articles

See all similar articles

Cited by 5 articles


    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. doi: 10.1016/S0140-6736(02)11911-8. - DOI - PubMed
    1. American Diabetes Association Treatment of hypertension in adults with diabetes. Position statement. Diabetes Care. 2003;26:80S–82. doi: 10.2337/diacare.26.7.2194. - DOI
    1. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. doi: 10.1016/S0195-668X(03)00114-3. - DOI - PubMed
    1. Lehnert H, Wittchen HU, Pittrow D, Bramlage P, Kirch W, Böhler S, Höfler M, Ritz E. Prävalenz und Pharmakoepidemiologie des Diabetes mellitus in Deutschland. Deutsche Med Wochenschr. 2005;130:323–328. doi: 10.1055/s-2005-863050. - DOI - PubMed
    1. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 1990;39:167–174. doi: 10.1016/0026-0495(90)90071-J. - DOI - PubMed

Publication types